CPSC
MRNA icon

Carl P. Sherr & Co’s Moderna MRNA Stock Holding History

Carl P. Sherr & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,043
Closed -$361K – 117
2024
Q2 		$361K Hold
3,043
– – 0.2% 90
2024
Q1 		$324K Hold
3,043
– – 0.18% 96
2023
Q4 		$303K Sell
3,043
-235
-7% -$19.8K 0.18% 93
2023
Q3 		$339K Buy
3,278
+221
+7% +$24.7K 0.23% 87
2023
Q2 		$371K Buy
3,057
+271
+10% +$36.2K 0.24% 85
2023
Q1 		$428K Sell
2,786
-451
-14% -$74.4K 0.31% 71
2022
Q4 		$581K Sell
3,237
-15
-0.5% -$2.45K 0.44% 57
2022
Q3 		$385K Sell
3,252
-150
-4% -$22.8K 0.31% 72
2022
Q2 		$486K Sell
3,402
-1,174
-26% -$168K 0.36% 71
2022
Q1 		$788K Sell
4,576
-319
-7% -$53.7K 0.53% 51
2021
Q4 		$1.24M Sell
4,895
-686
-12% -$201K 0.75% 32
2021
Q3 		$2.15M Sell
5,581
-13
-0.2% -$4.79K 1.71% 14
2021
Q2 		$1.31M Buy
5,594
+265
+5% +$47.4K 0.9% 32
2021
Q1 		$698K Buy
5,329
+102
+2% +$14.8K 0.53% 58
2020
Q4 		$546K Buy
5,227
+74
+1% +$7.49K 0.44% 67
2020
Q3 		$365K Buy
+5,153
New +$359K 0.33% 78

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carl P. Sherr & Co's MRNA Position: Q3 2024 in Review

Carl P. Sherr & Co sold out of Moderna (MRNA) in Q3 2024, closing a stake of 3,043 shares — an estimated $361K sold.

Carl P. Sherr & Co first reported a position in MRNA in Q3 2020 and held it in 16 quarters. The position peaked at $2.15M in Q3 2021. 789 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Carl P. Sherr & Co reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Carl P. Sherr & Co sold 3,043 Moderna shares in Q3 2024, an estimated $361K.
  • Carl P. Sherr & Co first reported a position in Moderna in Q3 2020 and held it in 16 quarters.
  • Carl P. Sherr & Co's Moderna position peaked at $2.15M in Q3 2021.
  • 789 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Carl P. Sherr & Co's 13F filing for Q3 2024, filed 14 Nov 2024.